DSM Biologics has entered an agreement to partner with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate a mammalian biopharmaceutical manufacturing facility in Brisbane. The 70,000 sq.-ft. facility will offer mammalian process development and cGMP clinical and commercial manufacturing services.

The Queensland State Government and the Commonwealth of Australia will provide full financial funding for the facility, which is part of the Queensland 10 year Biotechnology Strategic Plan. DSM will provide technological expertise to design and set up the facilities and will employ its portfolio of technologies. The services offered at the site will support all mammalian cell lines and process technologies including standard CHO-based systems and the PER.C6 cell-line technology.

Karen King, president of DSM Biologics said, “We are extremely honored to be selected by and partnering with the Australian Governments to bring Australia its first major cGMP mammalian CMO. This offering will be an important continuation and expansion of the services we currently provide out of our facility in Groningen, The Netherlands. Clients will have the added advantage of being able to choose between standard technology processes or Royal DSM’s proprietary XD and DSP optimization technologies.”